These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Are PPOs a competitive force or antitrust risk? Enders RJ Healthc Financ Manage; 1986 May; 40(5):52-60. PubMed ID: 10276171 [TBL] [Abstract][Full Text] [Related]
3. The development of preferred provider organizations and its antitrust implications. Maram BS J Med Pract Manage; 1985 Oct; 1(2):130-5. PubMed ID: 10281825 [TBL] [Abstract][Full Text] [Related]
4. Antitrust and the new competition in health care: excerpts. Ginsburg DH Med Prod Sales; 1986 Apr; 17(4):39-42. PubMed ID: 10276459 [No Abstract] [Full Text] [Related]
5. Court: Indiana Blues may adopt PPO plan without antitrust scrutiny. Allen HS; Rothschild IS Health Law Vigil; 1986 Apr; 9(8):4-5. PubMed ID: 10278389 [No Abstract] [Full Text] [Related]
6. Alternative delivery systems are focus of antitrust scrutiny. Scammon DL; Fuller DA; Sheffet MJ J Health Care Mark; 1987 Jun; 7(2):77-81. PubMed ID: 10282715 [No Abstract] [Full Text] [Related]
7. Federal antitrust agencies send mixed signals to PPOs. Enders RJ Health Care Law Newsl; 1986 Jul; 1(1):12-4. PubMed ID: 10277502 [No Abstract] [Full Text] [Related]
8. The FTC and provider-controlled PPO price negotiations. Miles JJ Health Law Vigil; 1988 Jan; 11(3):6-10. PubMed ID: 10285716 [No Abstract] [Full Text] [Related]
11. Proposed FTC consent order first to prohibit PPO price-fixing and concerted negotiations. Miles JJ Health Law Vigil; 1988 Jan; 11(2):9-10, 14. PubMed ID: 10285312 [No Abstract] [Full Text] [Related]
12. Monopolies, Maricopa, and marketing: a case study. Perkins J; Mercer A; McClary C Hosp Health Serv Adm; 1986; 31(4):34-44. PubMed ID: 10277339 [TBL] [Abstract][Full Text] [Related]
13. Preferred provider organizations: an antitrust warning. Sandler AL Group Pract J; 1987; 36(6):41-2, 44. PubMed ID: 10284861 [No Abstract] [Full Text] [Related]
14. Can provider antitrust suits against payers be successful? Enders RJ Healthc Financ Manage; 1986 Jun; 40(6):72-80. PubMed ID: 10276682 [TBL] [Abstract][Full Text] [Related]
15. Pharmacy participation in PPOs: an antitrust review. Health Matrix; 1984-1985 Winter; 2(4):35-7. PubMed ID: 10272758 [No Abstract] [Full Text] [Related]
16. PPOs: a challenge to HMOs? Kendrick M Group Health J; 1985; 6(2):22-7. PubMed ID: 10274981 [No Abstract] [Full Text] [Related]
17. More private, less government PPA antitrust action. Burda D Hospitals; 1987 Feb; 61(3):52. PubMed ID: 3804258 [No Abstract] [Full Text] [Related]
18. Preferred provider organizations and antitrust policy: some recent issues. Costillo LB Health Matrix; 1986; 4(2):22-5. PubMed ID: 10278618 [TBL] [Abstract][Full Text] [Related]
19. New breed of PPOs hold promise, but raise numerous legal questions. Gage LS; Bernard PE Bus Health; 1984 Dec; 2(2):47-8. PubMed ID: 10268901 [No Abstract] [Full Text] [Related]
20. Antitrust charges fail to slow PPA action by insurer. Burda D Hospitals; 1986 Apr; 60(8):68-70. PubMed ID: 3754236 [No Abstract] [Full Text] [Related] [Next] [New Search]